Human pluripotent stem cell-derived atrioventricular node-like pacemaker cells exhibit biological conduction bridge...

Area of Science:

• Cardiovascular Biology
• Stem Cell Therapy
• Regenerative Medicine

Background:

• The atrioventricular node (AVN) is crucial for synchronized heart contractions, connecting the atria and ventricles electrically.
• Dysfunction of AVN pacemaker cells causes atrioventricular block (AV block), a serious condition often treated with electronic pacemakers (EPMs).
• Existing EPMs have limitations, prompting research into alternatives like biological conduction bridges (BioCBs) derived from human pluripotent stem cells (hPSCs).

Purpose of the Study:

• To generate and characterize human pluripotent stem cell-derived atrioventricular node-like pacemaker cells (AVNLPCs).
• To evaluate the in vivo functional properties of transplanted AVNLPCs in a preclinical model.
• To explore the potential of AVNLPC-based BioCBs as a novel cell therapy for AV block.

Main Methods:

• AVNLPCs were differentiated from hPSCs using Wnt and BMP signaling modulation.
• Transcriptional profiling was performed to compare AVNLPCs with fetal AVN pacemaker cells.
• Electrophysiological properties and conduction characteristics of AVNLPCs were assessed.
• In vivo transplantation of AVNLPCs into guinea pig hearts was conducted to evaluate functional integration.

Main Results:

• hPSC differentiation yielded AVNLPCs that transcriptionally resemble fetal AVN pacemaker cells.
• AVNLPCs demonstrated characteristic pacemaker action potentials and unique AVN-like conduction properties.
• Transplanted AVNLPCs successfully replicated the functional properties of the native AVN in vivo.
• The study established the feasibility of using AVNLPCs for cell-based cardiac conduction therapy.

Conclusions:

• Human pluripotent stem cell-derived AVNLPCs possess functional and transcriptional characteristics of native AVN pacemaker cells.
• Transplanted AVNLPCs integrate and function within the heart, restoring conduction properties.
• An AVNLPC-based biological conduction bridge represents a promising novel cell therapy for treating atrioventricular block.